Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
about
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionNew targets for therapy in breast cancer: farnesyltransferase inhibitors.The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyEndocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerCyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivoMetastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cellsCrosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation.Motif-guided sparse decomposition of gene expression data for regulatory module identification.Estrogen receptors and proliferation markers in primary and recurrent breast cancerTissue architecture and breast cancer: the role of extracellular matrix and steroid hormonesTristetraprolin represses estrogen receptor α transactivation in breast cancer cellsGenomic index of sensitivity to endocrine therapy for breast cancer.KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis.BOLERO-2 - will this change practice in advanced breast cancer?Small molecule signal transduction inhibitors for the treatment of solid tumors.Treatment of breast cancer in older women.Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.Simultaneous targeting of estrogen receptor and HER2 in breast cancer.Breast cancer biomarker measurements and standards.Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation.S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy.Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells.Granulosa cell tumor of the ovary after long-term use of tamoxifen and toremifene.Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
P2860
Q24605762-A22ADD70-DFD1-4371-91D0-AADAC52D2957Q24796277-C34142D2-262C-466E-9C5C-A03D084E19BDQ24803648-49E034E1-5E55-481E-A646-684CACED5D51Q24813627-0A38D9F2-2B71-469E-B224-67981CE1F931Q27302901-EE9178A9-E58E-401E-992E-D672953825C7Q28237005-301D6F53-511B-4F6D-9598-83AB715653B9Q30434843-AC89EB29-C9CE-4C9D-A56B-D0E17682AC46Q33852615-C630C186-79CA-4BC3-9C25-243408542981Q33953032-1FDF85DC-8FFD-40C4-A430-8E6D3A73D870Q33974007-8C5A77A2-AE56-45D2-A360-C2DC552578F1Q34075981-D85700CD-52FB-44B1-8505-8D0E7E8DD299Q34193932-5921C75A-E12E-40F7-8F52-5A611786ADFEQ34205192-BE3D85B2-1A13-4FA6-9382-38747DE8CD89Q34781067-54C54187-93FE-4094-B385-68872F030D8AQ35631641-28992DC0-BFA9-4355-A763-3D8BA99E4AA6Q35786706-08213919-2296-478C-B826-636B8EDFA68CQ36157213-249B21C0-BD4F-4723-8D50-BF677C1E8B61Q36245315-01FF32B9-EE1B-4033-B5B0-5D09AF6B57BAQ36895413-32ACEA45-05C9-4083-912B-72D47BDF0F9AQ36953425-81CBC353-6260-4AB1-9CCB-1E0EF50F11E5Q37442623-03233753-3B88-4447-8749-46924BCABB39Q37782093-2A337842-4284-4398-BBDD-A3DA496F4C84Q38076082-7950122D-6DBB-4156-8D51-30120D291E58Q39485529-13993133-0F2B-4557-B42A-D8C3F7D64388Q39772743-0353193A-193A-403D-BE45-55A77B325E99Q39900962-600DE6EA-76C6-4CA7-A143-4177C4731ABDQ40453538-8DC40BF4-D99E-491B-A697-C7F8A874AA39Q41780559-72709C3F-2DAA-4117-91EC-089F9AE38602Q43678719-5098BA14-983A-4DA9-9075-AA76DDD10E42Q51184967-F0B18AB1-5F1F-4F08-8B2E-A7341CBF9C6BQ53471682-D85F7AB3-6B74-405B-B9E2-733F7643F4DB
P2860
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Involvement of steroid hormone ...... ine response in breast cancer.
@ast
Involvement of steroid hormone ...... ine response in breast cancer.
@en
type
label
Involvement of steroid hormone ...... ine response in breast cancer.
@ast
Involvement of steroid hormone ...... ine response in breast cancer.
@en
prefLabel
Involvement of steroid hormone ...... ine response in breast cancer.
@ast
Involvement of steroid hormone ...... ine response in breast cancer.
@en
P2093
P356
P1476
Involvement of steroid hormone ...... ine response in breast cancer.
@en
P2093
McClelland RA
Nicholson RI
Robertson JF
P304
P356
10.1677/ERC.0.0060373
P577
1999-09-01T00:00:00Z